Assessment of Quality of Life of Children With Chronic Idiopathic Thrombocytopenic Purpura (Kid's ITP Tools)

NCT ID: NCT03123497

Last Updated: 2020-03-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

183 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-04-12

Study Completion Date

2020-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Assessment of quality of life of patient with chronic idiopathic thrombocytopenic purpura according to the type of treatment

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Thrombocytopenic Purpura

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Idiopathic Thrombocytopenic Purpura

completion of questionnaire

completion of questionnaire

Intervention Type OTHER

completion of questionnaire for patient and parent

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

completion of questionnaire

completion of questionnaire for patient and parent

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* children with Idiopathic thrombocytopenic purpura
* aged between 1 and 17 year
* Idiopathic thrombocytopenic purpura persistent at 12 months
* obtention of informed consent

Exclusion Criteria

* Persistant/acute Idiopathic thrombocytopenic purpura
* concomittant chronic disease, stabilized or not
* Concomittant disease with life expectancy \< 1 year
* Person who have not belong to a social security scheme
* Secondary Idiopathic thrombocytopenic purpura
Minimum Eligible Age

1 Year

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Angers

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Isabelle Pellier, Pr

Role: PRINCIPAL_INVESTIGATOR

chu

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU d'Angers

Angers, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

marianne roumy

Role: CONTACT

0241356385 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Marianne Roumy

Role: primary

0241356385 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

49RC17_0011

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Eltrombopag in Chronic ITP
NCT04102033 UNKNOWN PHASE4